Open Access

Prognostic factors and survival according to tumor subtype in newly diagnosed breast cancer with liver metastases: A competing risk analysis

  • Authors:
    • Qi‑Feng Chen
    • Tao Huang
    • Lujun Shen
    • Peihong Wu
    • Zi‑Lin Huang
    • Wang Li
  • View Affiliations

  • Published online on: July 1, 2019     https://doi.org/10.3892/mco.2019.1890
  • Pages: 259-269
  • Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Population‑based study for predicting the prognosis for breast cancer liver metastasis (BCLM) is lacking at present. Therefore, the present study aimed to evaluate newly diagnosed BCLM patients of different tumor subtypes and assess potential prognostic factors for predicting the survival for BCLM patients. Specifically, data were collected from the Surveillance, Epidemiology and End Results program from 2010 to 2014, and were assessed, including the data of patients with BCLM. Differences in the overall survival (OS) among patients was compared via Kaplan‑Meier analysis. Other prognostic factors of OS were determined using the Cox proportional hazard model. In addition, the breast cancer‑specific mortality was assessed using the Fine and Gray's competing risk model. A nomogram was also constructed on the basis of the Cox model for predicting the prognosis of BCLM cases. A total of 2,098 cases that had a median OS of 20.0 months were included. The distribution of tumor subtypes was as follows: 42.2% with human epidermal growth factor receptor 2 (Her2; ‑)/hormone receptor (HR; +), 12.8% with Her2(+)/HR(‑), 19.1% with Her2(+)/HR(+) and 13.5% with triple negative breast cancer (TNBC). Kaplan‑Meier analysis revealed that older age (>64 years), unmarried status, larger tumor, higher grade, no surgery, metastases at other sites, and TNBC subtype were associated with shorter OS. Additionally, multivariate analysis revealed that older age (>64 years), unmarried status, no surgery, bone metastasis, brain metastasis and TNBC subtype were significantly associated with worse prognosis. Thus, age at diagnosis, marital status, surgery, bone metastasis, brain metastasis and tumor subtype were confirmed as independent prognosis factors from a competing risk model. We also constructed a nomogram, which had the concordance index of internal validation of 0.685 (0.650‑0.720). This paper had carried out the population‑based prognosis prediction for BCLM cases. The survival of BCLM differed depending on the tumor subtype. More independent prognosis factors were age at the time of diagnosis, surgery, marital status, bone metastasis, as well as brain metastasis, in addition to tumor subtype. Notably, the as‑constructed nomogram might serve as an efficient approach to predict the prognosis for individual patients.

References

1 

DeSantis CE, Bray F, Ferlay J, Lortet-Tieulent J, Anderson BO and Jemal A: International variation in female breast cancer incidence and mortality rates. Cancer Epidemiol Biomarkers Prev. 24:1495–1506. 2015. View Article : Google Scholar : PubMed/NCBI

2 

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI

3 

Servick K: Breast cancer. Breast cancer: A world of differences. Science. 343:1452–1453. 2014. View Article : Google Scholar : PubMed/NCBI

4 

Malvezzi M, Bertuccio P, Levi F, La Vecchia C and Negri E: European cancer mortality predictions for the year 2012. Ann Oncol. 23:1044–1052. 2012. View Article : Google Scholar : PubMed/NCBI

5 

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI

6 

Jemal A, Center MM, DeSantis C and Ward EM: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 19:1893–1907. 2010. View Article : Google Scholar : PubMed/NCBI

7 

Golse N and Adam R: Liver metastases from breast cancer: What role for surgery? Indications and Results. Clin Breast Cancer. 17:256–265. 2017. View Article : Google Scholar : PubMed/NCBI

8 

Soni A, Ren Z, Hameed O, Chanda D, Morgan CJ, Siegal GP and Wei S: Breast cancer subtypes predispose the site of distant metastases. Am J Clin Pathol. 143:471–478. 2015. View Article : Google Scholar : PubMed/NCBI

9 

Savci-Heijink CD, Halfwerk H, Hooijer GK, Horlings HM, Wesseling J and van de Vijver MJ: Retrospective analysis of metastatic behaviour of breast cancer subtypes. Breast Cancer Res Treat. 150:547–557. 2015. View Article : Google Scholar : PubMed/NCBI

10 

O'Reilly SM, Richards MA and Rubens RD: Liver metastases from breast cancer: The relationship between clinical, biochemical and pathological features and survival. Eur J Cancer. 26:574–577. 1990. View Article : Google Scholar : PubMed/NCBI

11 

Wyld L, Gutteridge E, Pinder SE, James JJ, Chan SY, Cheung KL, Robertson JF and Evans AJ: Prognostic factors for patients with hepatic metastases from breast cancer. Br J Cancer. 89:284–290. 2003. View Article : Google Scholar : PubMed/NCBI

12 

Atalay G, Biganzoli L, Renard F, Paridaens R, Cufer T, Coleman R, Calvert AH, Gamucci T, Minisini A, Therasse P, et al: Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: A retrospective analysis of two prospective, randomised metastatic breast cancer trials. Eur J Cancer. 39:2439–2449. 2003. View Article : Google Scholar : PubMed/NCBI

13 

Duan XF, Dong NN, Zhang T and Li Q: The prognostic analysis of clinical breast cancer subtypes among patients with liver metastases from breast cancer. Int J Clin Oncol. 18:26–32. 2013. View Article : Google Scholar : PubMed/NCBI

14 

Rossi M, Carioli G, Bonifazi M, Zambelli A, Franchi M, Moja L, Zambon A, Corrao G, La Vecchia C, Zocchetti C and Negri E: Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival. Eur J Cancer. 52:41–49. 2016. View Article : Google Scholar : PubMed/NCBI

15 

Toft DJ and Cryns VL: Minireview: Basal-like breast cancer: From molecular profiles to targeted therapies. Mol Endocrinol. 25:199–211. 2011. View Article : Google Scholar : PubMed/NCBI

16 

Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, et al: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 11:5678–5685. 2005. View Article : Google Scholar : PubMed/NCBI

17 

Largillier R, Ferrero JM, Doyen J, Barriere J, Namer M, Mari V, Courdi A, Hannoun-Levi JM, Ettore F, Birtwisle-Peyrottes I, et al: Prognostic factors in 1,038 women with metastatic breast cancer. Ann Oncol. 19:2012–2019. 2008. View Article : Google Scholar : PubMed/NCBI

18 

Follana P, Barriere J, Chamorey E, Largillier R, Dadone B, Mari V, Hannoun-Levi JM, Marcy M, Flipo B and Ferrero JM: Prognostic factors in 401 elderly women with metastatic breast cancer. Oncology. 86:143–151. 2014. View Article : Google Scholar : PubMed/NCBI

19 

Leone JP, Leone J, Zwenger AO, Iturbe J, Leone BA and Vallejo CT: Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis. Eur J Cancer. 74:17–25. 2017. View Article : Google Scholar : PubMed/NCBI

20 

Martin AM, Cagney DN, Catalano PJ, Warren LE, Bellon JR, Punglia RS, Claus EB, Lee EQ, Wen PY, Haas-Kogan DA, et al: Brain metastases in newly diagnosed breast cancer: A population-based study. JAMA Oncol. 3:1069–1077. 2017. View Article : Google Scholar : PubMed/NCBI

21 

Leone BA, Vallejo CT, Romero AO, Machiavelli MR, Pérez JE, Leone J and Leone JP: Prognostic impact of metastatic pattern in stage IV breast cancer at initial diagnosis. Breast Cancer Res Treat. 161:537–548. 2017. View Article : Google Scholar : PubMed/NCBI

22 

Gong Y, Liu YR, Ji P, Hu X and Shao ZM: Impact of molecular subtypes on metastatic breast cancer patients: A SEER population-based study. Sci Rep. 7:454112017. View Article : Google Scholar : PubMed/NCBI

23 

Wu SG, Li H, Tang LY, Sun JY, Zhang WW, Li FY, Chen YX and He ZY: The effect of distant metastases sites on survival in de novo stage-IV breast cancer: A SEER database analysis. Tumour Biol. 39:10104283177050822017. View Article : Google Scholar : PubMed/NCBI

24 

Scrucca L, Santucci A and Aversa F: Competing risk analysis using R: An easy guide for clinicians. Bone Marrow Transplant. 40:381–387. 2007. View Article : Google Scholar : PubMed/NCBI

25 

Zhao HY, Gong Y, Ye FG, Ling H and Hu X: Incidence and prognostic factors of patients with synchronous liver metastases upon initial diagnosis of breast cancer: A population-based study. Cancer Manag Res. 10:5937–5950. 2018. View Article : Google Scholar : PubMed/NCBI

26 

Wang M, Zhang J, Ji S, Shao G, Zhao K, Wang Z and Wu A: Transarterial chemoembolisation for breast cancer with liver metastasis: A systematic review. Breast. 36:25–30. 2017. View Article : Google Scholar : PubMed/NCBI

27 

Tewes M, Peis MW, Bogner S, Theysohn JM, Reinboldt MP, Schuler M and Welt A: Hepatic arterial infusion chemotherapy for extensive liver metastases of breast cancer: Efficacy, safety and prognostic parameters. J Cancer Res Clin Oncol. 143:2131–2141. 2017. View Article : Google Scholar : PubMed/NCBI

28 

Wang H, Liu B, Long H, Zhang F, Wang S and Li F: Clinical study of radiofrequency ablation combined with TACE in the treatment of breast cancer with liver metastasis. Oncol Lett. 14:2699–2702. 2017. View Article : Google Scholar : PubMed/NCBI

29 

Kimbung S, Loman N and Hedenfalk I: Clinical and molecular complexity of breast cancer metastases. Semin Cancer Biol. 35:85–95. 2015. View Article : Google Scholar : PubMed/NCBI

30 

Kwast AB, Voogd AC, Menke-Pluijmers MB, Linn SC, Sonke GS, Kiemeney LA and Siesling S: Prognostic factors for survival in metastatic breast cancer by hormone receptor status. Breast Cancer Res Treat. 145:503–511. 2014. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

September 2019
Volume 11 Issue 3

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Chen, Q., Huang, T., Shen, L., Wu, P., Huang, Z., & Li, W. (2019). Prognostic factors and survival according to tumor subtype in newly diagnosed breast cancer with liver metastases: A competing risk analysis. Molecular and Clinical Oncology, 11, 259-269. https://doi.org/10.3892/mco.2019.1890
MLA
Chen, Q., Huang, T., Shen, L., Wu, P., Huang, Z., Li, W."Prognostic factors and survival according to tumor subtype in newly diagnosed breast cancer with liver metastases: A competing risk analysis". Molecular and Clinical Oncology 11.3 (2019): 259-269.
Chicago
Chen, Q., Huang, T., Shen, L., Wu, P., Huang, Z., Li, W."Prognostic factors and survival according to tumor subtype in newly diagnosed breast cancer with liver metastases: A competing risk analysis". Molecular and Clinical Oncology 11, no. 3 (2019): 259-269. https://doi.org/10.3892/mco.2019.1890